Zealand Pharma A/S (NASDAQ:ZEAL) has received a consensus broker rating score of 1.83 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company.

Analysts have set a twelve-month consensus target price of $27.33 for the company and are anticipating that the company will post ($0.36) earnings per share for the current quarter, according to Zacks. Zacks has also given Zealand Pharma A/S an industry rank of 105 out of 265 based on the ratings given to its competitors.

Several research firms have recently weighed in on ZEAL. Morgan Stanley began coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They set an “overweight” rating and a $28.00 price target for the company. Guggenheim began coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They set a “buy” rating and a $28.00 price target for the company. Needham & Company LLC began coverage on shares of Zealand Pharma A/S in a research note on Tuesday, September 5th. They set a “buy” rating and a $26.00 price target for the company. Finally, Goldman Sachs Group, Inc. (The) began coverage on shares of Zealand Pharma A/S in a research note on Wednesday, September 27th. They set a “buy” rating for the company.

Zealand Pharma A/S (ZEAL) traded up 0.11% on Wednesday, hitting $19.03. The company’s stock had a trading volume of 10,857 shares. Zealand Pharma A/S has a 12 month low of $16.07 and a 12 month high of $20.37. The firm’s market cap is $585.15 million. The firm has a 50 day moving average of $18.98 and a 200 day moving average of $18.65.

ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/04/zacks-analysts-set-27-33-target-price-for-zealand-pharma-as-zeal.html.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes.

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.